https://scholars.lib.ntu.edu.tw/handle/123456789/634900
標題: | Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia | 作者: | Cao, Y Qin, S Luo, S Li, Z Cheng, Y Fan, Y Sun, Y Yin, X Yuan, X Li, W Liu, T CHIH-HUNG HSU Lin, X Kim, S-B Kojima, T Zhang, J Lee, S-H Bai, Y Muro, K Doi, T Bai, C Gu, K Pan, H-M Bai, L Yang, J-W Cui, Y Lu, W Chen, J |
關鍵字: | PD-1; PD-L1 CPS; esophageal squamous cell carcinoma; pembrolizumab | 公開日期: | 二月-2022 | 卷: | 7 | 期: | 1 | 來源出版物: | ESMO open | 摘要: | In the randomized phase III KEYNOTE-181 study, pembrolizumab prolonged overall survival (OS) compared with chemotherapy as second-line therapy in patients with advanced esophageal cancer and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10. We report a post hoc subgroup analysis of patients with esophageal squamous cell carcinoma (ESCC) enrolled in KEYNOTE-181 in Asia, including patients from the KEYNOTE-181 China extension study. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634900 | ISSN: | 20597029 | DOI: | 10.1016/j.esmoop.2021.100341 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。